Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.69 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.57 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CTRC | Q99895 | 1/20 | 0.56 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.56 |
| ▸ | ERN1 | O75460 | 2/20 | 0.56 |
| ▸ | RXRA | P19793 | 1/20 | 0.56 |
| ▸ | RXRB | P28702 | 1/20 | 0.56 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29923455 | 0.92 | KMO (0.68) | KMOSIRT2LMNAGAAERN1 | |
| SCHEMBL14743086 | 0.92 | KMO (0.68) | KMOSIRT2LMNAGAAERN1 | |
| SCHEMBL14758851 | 0.91 | KMO (0.66) | KMOSIRT2LMNAGAAERN1 | |
| SCHEMBL18965053 | 0.87 | ATM (0.59) | KMOSIRT2ACMSDHSD17B1HSD17B2 | |
| SCHEMBL6836496 | 0.87 | CTRC (0.62) | KMOSIRT2ACMSDCTRCHSD17B1 | |
| SCHEMBL3220396 | 0.86 | KMO (0.91) | KMOLMNAGAAERN1RXRA | |
| SCHEMBL3020903 | 0.86 | ESR1 (0.65) | KMOLMNAGAAHSD17B1HSD17B2 | |
| SCHEMBL2036894 | 0.85 | ACMSD (0.61) | KMOACMSDCTRCRXRARXRB | |
| SCHEMBL2310774 | 0.85 | KMO (0.62) | KMOACMSDLMNAGAARXRA | |
| SCHEMBL29788052 | 0.85 | ACMSD (0.61) | KMOACMSDCTRCRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210101861-A1 | NOVEL REXINOID COMPOUNDS AND METHODS OF USING REXINOID COMPOUNDS FOR TREATING METABOLIC DISORDERS AND CANCER | THE UAB RESEARCH FOUNDATION (US) | 2021-04-08 | — | — | US | disclosed |
| US-10800726-B2 | Rexinoid compounds and methods of using rexinoid compounds for treating metabolic disorders and cancer | THE UAB RESEARCH FOUNDATION (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3160508-B1 | NOVEL REXINOID COMPOUNDS AND METHODS OF USING REXINOID COMPOUNDS FOR TREATING METABOLIC DISORDERS AND CANCER | UAB RES FOUND (US) | 2020-08-05 | — | — | EP | disclosed |
| US-20180201565-A1 | NOVEL REXINOID COMPOUNDS AND METHODS OF USING REXINOID COMPOUNDS FOR TREATING METABOLIC DISORDERS AND CANCER | THE UAB RESEARCH FOUNDATION (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180201565-A1 | NOVEL REXINOID COMPOUNDS AND METHODS OF USING REXINOID COMPOUNDS FOR TREATING METABOLIC DISORDERS AND CANCER | THE UAB RESEARCH FOUNDATION (US) | 2018-07-19 | — | — | US | disclosed |
| WO-2016004066-A1 | NOVEL REXINOID COMPOUNDS AND METHODS OF USING REXINOID COMPOUNDS FOR TREATING METABOLIC DISORDERS AND CANCER | THE UAB RESEARCH FOUNDATION (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2008057543-A2 | UII-MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057543-A2 | UII-MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| CN-1080257-C | Guanidine derivatives as inhibitors of Na+/H+ exchange in cells | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-03-06 | — | — | CN | disclosed |
| EP-0699185-B1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-5824691-A | CARDIOVASCULAR, CEREBROVASCULAR, RENAL DISEASES; SHOCK, ARTERIOSCLEROSIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-20 | — | — | US | disclosed |
| CN-1123545-A | Guanidine derivatives as inhibitors of Na+/H+ exchange in cells | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-05-29 | — | — | CN | disclosed |
| EP-0699185-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994026709-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201565-A1 | NOVEL REXINOID COMPOUNDS AND METHODS OF USING REXINOID COMPOUNDS FOR TREATING METABOLIC DISORDERS AND CANCER | GPR119, PNLIP, RXRG | KMO 4000/4885SIRT2 648/4885ACMSD 4349/4885 |
| US-10800726-B2 | Rexinoid compounds and methods of using rexinoid compounds for treating metabolic disorders and cancer | GPR119, PNLIP, LIPC | KMO 3852/4885SIRT2 644/4885ACMSD 4361/4885 |
| US-20210101861-A1 | NOVEL REXINOID COMPOUNDS AND METHODS OF USING REXINOID COMPOUNDS FOR TREATING METABOLIC DISORDERS AND CANCER | GPR119, PNLIP, RXRG | KMO 4000/4885SIRT2 648/4885ACMSD 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.